Source-grounded facts extracted from Kalaris Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Laurie Keating was elected as Director at Kalaris Therapeutics, Inc..
“On July 3, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board elected Laurie Keating to serve as a member of the Board, effective as of August 1, 2026.”
Morana Jovan-Embiricos resigned as Director at Kalaris Therapeutics, Inc..
“On July 3, 2026, Morana Jovan-Embiricos, Ph.D., notified Kalaris Therapeutics, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.”
Kalaris Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.
“The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Kalaris Therapeutics, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2026-06-03 meeting.
“The stockholders of the Company recommended, on a non-binding advisory basis, that future advisory votes on the compensation of the Company's named executive officers be held every year.”
Kalaris Therapeutics, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-06-03 meeting.
“The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.”
Kalaris Therapeutics, Inc. shareholders approved Election of Class III directors Napoleone Ferrara, M.D., David Hallal and Leone Patterson at the 2026-06-03 meeting.
“The stockholders of the Company elected Napoleone Ferrara, M.D., David Hallal and Leone Patterson as Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified.”
Kalaris Therapeutics, Inc. reported financial results for quarter ended March 31, 2026.
“Research and Development Expenses : Research and development expenses were $7.6 million for the quarter ended March 31, 2026, compared with $6.0 million for the quarter ended March 31, 2025.”
Kalaris Therapeutics, Inc. reported the year ended December 31, 2025 results: net income net loss was $43.4 million.
“On March 17, 2026, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the year ended December 31, 2025.”
Kalaris Therapeutics, Inc. issued pre-funded warrants to purchase 800,000 shares of warrant to certain Investors for $9.9999 per Pre-Funded Warrant.
“pre-funded warrants to purchase 800,000 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a price of $9.9999 per Pre-Funded Warrant”
Kalaris Therapeutics, Inc. issued 4,200,000 shares of common stock to certain institutional accredited investors for $10.00 per Share.
“the Company agreed to issue and sell to the Investors in a private placement an aggregate of 4,200,000 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $10.00 per Share”
Leone Patterson was elected as Director and Chair of Audit Committee at Kalaris Therapeutics, Inc..
“On April 3, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”), the Board elected Leone Patterson to serve as a member of the Board, effective immediately.”
Kalaris Therapeutics, Inc.: Combined Company ceased to be a shell company as a result of the merger.
“As a result of the Merger, the Combined Company ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the Closing.”
Kalaris Therapeutics, Inc.: Removed reverse stock split provisions from restated charter (effective 2025-01-15).
“Effective as of 4:03 p.m., Eastern Time on the Closing Date, the Combined Company restated the Certificate of Incorporation (as restated, the “Restated Charter”) and removed certain provisions that effectuated a reverse stock split of issued and outstanding shares of AlloVir Common Stock on January 15, 2025.”
Kalaris Therapeutics, Inc.: Amended and restated by-laws solely to reflect company name change.
“In connection with the Name Change, the Board also approved an amendment and restatement of the Company’s Amended and Restated By-Laws solely to reflect the Name Change (the “Amended and Restated By-Laws”), effective as of the Closing Date.”
Kalaris Therapeutics, Inc.: Amended certificate of incorporation to change company name from AlloVir, Inc. to Kalaris Therapeutics, Inc.
“Effective as of 4:02 p.m., Eastern Time on the Closing Date, the Combined Company amended its Third Amended and Restated Certificate of Incorporation, as amended (as may be further amended from time to time, the “Certificate of Incorporation” and such amendment, the “Charter Amendment”), to effect a change of the Combined Company’s name from “AlloVir, Inc.” to “Kalaris Therapeutics, Inc.” (the “Name Change”).”
Kalaris Therapeutics, Inc. underwent a change of control involving Legacy Kalaris for 13,634,744 shares of Combined Company Common Stock (closed 2025-03-18).
“of shares of Combined Company Common Stock that AlloVir issued to Legacy Kalaris’ securityholders (including all holders of outstanding convertible notes) at the Closing is 13,634,744, resulting in approximately 18,702,413 shares of Combined Company Common Stock, being issued and outstanding immediately following the Effective Time. This number reflects, as of”
Andrew Oxtoby was appointed as President and Chief Executive Officer at Kalaris Therapeutics, Inc..
“Mr. Oxtoby, age 51, has served as the Combined Company’s President and Chief Executive Officer and as a member of the Board since the Closing.”
David Hallal was appointed as Chair of the Board at Kalaris Therapeutics, Inc..
“David Hallal was appointed Chair of the Board.”
Samir Patel was appointed as Director at Kalaris Therapeutics, Inc..
“the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.”
Napoleone Ferrara was appointed as Director at Kalaris Therapeutics, Inc..
“the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.”
Michael Dybbs was appointed as Director at Kalaris Therapeutics, Inc..
“the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.”
Srinivas Akkaraju was appointed as Director at Kalaris Therapeutics, Inc..
“the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.”
Anthony Adamis was appointed as Director at Kalaris Therapeutics, Inc..
“the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.”
Andrew Oxtoby was appointed as Director at Kalaris Therapeutics, Inc..
“the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.”
Morana Jovan-Embiricos was appointed as Director at Kalaris Therapeutics, Inc..
“the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.”
David Hallal was appointed as Director at Kalaris Therapeutics, Inc..
“the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.”
Juan Vera resigned as Director at Kalaris Therapeutics, Inc..
“at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board”
Shawn Tomasello resigned as Director at Kalaris Therapeutics, Inc..
“at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board”
Jeffrey S. Bornstein resigned as Director at Kalaris Therapeutics, Inc..
“at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board”
Malcom Brenner resigned as Director at Kalaris Therapeutics, Inc..
“at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board”
Derek Adams resigned as Director at Kalaris Therapeutics, Inc..
“at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board”
Vikas Sinha resigned as Director at Kalaris Therapeutics, Inc..
“at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board”
Kalaris Therapeutics, Inc.: Reverse stock split of common stock at 1-for-23 ratio via Certificate of Amendment to Third Amended and Restated Certificate of Incorporation (effective 2025-01-15).
“On January 15, 2025, AlloVir, Inc. (“AlloVir”) filed an amendment (the “Certificate of Amendment”) to its Third Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of AlloVir’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).”
Kalaris Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“February 9, 2024, AlloVir, Inc. (“AlloVir”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of AlloVir’s common stock was below $1.00 per share for 30 consecutive business days, and that, therefore, AlloVir is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The notice from Nasdaq has no immediate effect on the listing of AlloVir’s common stock, and the common stock will continue to be listed on the Nasdaq Global Select Market under the”
Kalaris Therapeutics, Inc. announced a restructuring with charges of approximately $13 million (approximately 95% of AlloVir’s current employee base).
“2024 and expects to be substantially completed by April 15, 2024. As a result of these actions, AlloVir expects to incur personnel-related restructuring charges of approximately $13 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the first quarter”
Kalaris Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income net loss was $44.3 million or $0.39 per share, EPS $0.39 per share.
“On November 2, 2023, AlloVir, Inc. announced its financial results for the quarter ended September 30, 2023.”
Kalaris Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income net loss was $45.3 million or $0.48 per share, EPS $0.48 per share. Guidance reaffirmed.
“For the quarter ended June 30, 2023, net loss was $45.3 million or $0.48 per share compared with a net loss of $44.6 million or $0.69 per share for the quarter ended June 30, 2022.”
Kalaris Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BoFA Securities, Inc., as the representatives of the several underwriters valued at $3.75 per share (effective 2023-06-21).
“On June 21, 2023, AlloVir, Inc. (“AlloVir”) entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BoFA Securities, Inc., as the representatives of the several underwriters (the “Underwriters”) relating to an underwritten public offering of 20,000,000 shares of its common stock, par value $0.0001 per share, at a price to the public of $3.75 per share, less underwriting discounts and commissions.”
Kalaris Therapeutics, Inc.: Increased authorized shares of common stock from 150,000,000 to 300,000,000 (effective 2023-05-15).
“On May 15, 2023, AlloVir, Inc. (the “Company”) filed a certificate of amendment to its amended and restated certificate of incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware to increase the authorized shares of common stock from 150,000,000 to 300,000,000.”
Kalaris Therapeutics, Inc. shareholders approved Amendment to Third Amended and Restated Certificate of Incorporation to increase authorized common shares from 150,000,000 to 300,000,000 at the 2023-05-11 meeting.
“For Against Abstain 86,571,410 544,049 1,225”
Kalaris Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-11 meeting.
“For Against Abstain 86,411,460 689,359 15,865”
Kalaris Therapeutics, Inc. shareholders approved Election of Class III directors: Jeffrey Bornstein, Diana Brainard, M.D., David Hallal, Shawn Tomasello at the 2023-05-11 meeting.
“The Company’s stockholders approved the Class III director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for the Class III directors as follows: Class III Director Nominee For Withhold Broker Non- Votes Jeffrey Bornstein 51,184,647 11,888,021 24,044,016 Diana Brainard, M.D. 54,972,729 8,099,939 24,044,016 David Hallal 54,298,062 8,774,606 24,044,016 Shawn Tomasello 51,020,208 12,052,460 24,044,016”
Kalaris Therapeutics, Inc. updated its fiscal year 2023 guidance (initiated).
“For fiscal year 2023, AlloVir expects operating expenses to be in the range of $150 million to $170 million, excluding non-cash expenses.”
Kalaris Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $41.2 million, EPS $0.44 per share.
“For the quarter ended March 31, 2023, net loss was $41.2 million or $0.44 per share compared with a net loss of $43.9 million or $0.69 per share for the quarter ended March 31, 2022.”
Ansbert Gadicke retired as Director at Kalaris Therapeutics, Inc..
“Ansbert Gadicke, M.D. notified the Board that he will be retiring from the Board effective February 28, 2023.”
Derek Adams was appointed as Director at Kalaris Therapeutics, Inc..
“the Board appointed Derek Adams, Ph.D. to the Board, effective March 1, 2023, to fill a newly created vacancy resulting from the retirement of Ansbert Gadicke, M.D.”
Kalaris Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.
“On February 15, 2023, AlloVir, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022.”
Kalaris Therapeutics, Inc. updated its fiscal year 2023 guidance (initiated).
“For fiscal year 2023, AlloVir expects operating expenses to be in the range of $150 million to $170 million, excluding non-cash stock compensation expenses.”
Jeroen van Beek resigned as Executive Vice President and Chief Commercial Officer at Kalaris Therapeutics, Inc..
“On November 21, 2022, AlloVir, Inc. (“AlloVir” or the “Company”) announced that Jeroen van Beek, the Company’s Executive Vice President and Chief Commercial Officer, has resigned from the Company effective as of November 23, 2022 to pursue new opportunities.”
Kalaris Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 3, 2022, AlloVir, Inc. announced its financial results for the quarter ended September 30, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.